Valuation: Galapagos NV

Market Cap 1.57B 0 1.81B 1.46B 1.34B 2.54B 173B 2.58B 17.25B 6.77B 86.12B 6.81B 6.66B 285B P/E 2026 *
-11.2x
P/E 2027 * -8.45x
Enterprise Value -411M -0 -474M -382M -351M -664M -45.17B -674M -4.51B -1.77B -22.51B -1.78B -1.74B -74.59B EV / Sales 2026 *
-28.9x
EV / Sales 2027 * -9.14x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.50%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.60%+2.03%+76.87%+128.10%

Financials

2026 *2027 *
Net sales 14.24M 0 16.42M 13.25M 12.18M 23.01M 1.57B 23.37M 156M 61.36M 780M 61.64M 60.29M 2.58B 46.09M 0 53.13M 42.89M 39.41M 74.46M 5.07B 75.63M 506M 199M 2.52B 199M 195M 8.36B
Net income -811M -0 -935M -754M -693M -1.31B -89.1B -1.33B -8.89B -3.49B -44.4B -3.51B -3.43B -147B -238M -0 -274M -221M -203M -384M -26.14B -390M -2.61B -1.02B -13.02B -1.03B -1.01B -43.16B
Net Debt -1.98B -0 -2.29B -1.85B -1.7B -3.2B -218B -3.25B -21.76B -8.55B -109B -8.58B -8.4B -360B -1.99B -0 -2.3B -1.86B -1.7B -3.22B -219B -3.27B -21.87B -8.59B -109B -8.63B -8.44B -362B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B